We narrowed to 253 results for: cha;

1. AiP14825: pAAV-AiE0441h_3xC2-minBG-iCre(R297T)-BGHpA (Alias: CN4825) (AAV PHP.eB)

   Viral Prep

   #214862-PHPeB

   Purpose

   Ready-to-use AAV PHP.eB particles produced from AiP14825: pAAV-AiE0441h_3xC2-minBG-iCre(R297T)-BGHpA (Alias: CN4825) (#214862). In addition to the viral particles, you will also receive purified AiP14825: pAAV-AiE0441h_3xC2-minBG-iCre(R297T)-BGHpA (Alias: CN4825) plasmid DNA. minBG-driven expression of iCre(R297T) in striatal medium spiny neurons. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

   Depositor

   The Allen Institute for Brain Science, Jonathan Ting

   Article

   Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

   Promoter

   Tags

   None

   Available since

   Nov. 13, 2024

   Availability

   Academic Institutions and Nonprofits only

2. AiP13863 - pAAV-AiE0888m_C4-minBG-SYFP2-WPRE3-BGHpA (Alias: CN3863) (AAV PHP.eB)

   Viral Prep

   #199773-PHPeB

   Purpose

   Ready-to-use AAV PHP.eB particles produced from AiP13863 - pAAV-AiE0888m_C4-minBG-SYFP2-WPRE3-BGHpA (Alias: CN3863) (#199773). In addition to the viral particles, you will also receive purified AiP13863 - pAAV-AiE0888m_C4-minBG-SYFP2-WPRE3-BGHpA (Alias: CN3863) plasmid DNA. SYFP2 expression in midbrain dopamine neurons. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

   Depositor

   The Allen Institute for Brain Science, Jonathan Ting

   Article

   Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

   Promoter

   Tags

   SYFP2

   Available since

   July 15, 2024

   Availability

   Academic Institutions and Nonprofits only

3. AiP13905 - pAAV-AiE0441h_3xC2-minBG-SYFP2-WPRE3-BGHpA (Alias: CN3905) (AAV PHP.eB)

   Viral Prep

   #199774-PHPeB

   Purpose

   Ready-to-use AAV PHP.eB particles produced from AiP13905 - pAAV-AiE0441h_3xC2-minBG-SYFP2-WPRE3-BGHpA (Alias: CN3905) (#199774). In addition to the viral particles, you will also receive purified AiP13905 - pAAV-AiE0441h_3xC2-minBG-SYFP2-WPRE3-BGHpA (Alias: CN3905) plasmid DNA. SYFP2 expression in all striatal medium spiny neurons. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

   Depositor

   The Allen Institute for Brain Science, Jonathan Ting

   Article

   Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

   Promoter

   Tags

   SYFP2

   Available since

   July 15, 2024

   Availability

   Academic Institutions and Nonprofits only

4. AiP13755: pAAV-AiE0743m_3xC2-minBG-ChR2(H134R)-EYFP-WPRE3-BGHpA (Alias: CN3755) (AAV PHP.eB)

   Viral Prep

   #214846-PHPeB

   Purpose

   Ready-to-use AAV PHP.eB particles produced from AiP13755: pAAV-AiE0743m_3xC2-minBG-ChR2(H134R)-EYFP-WPRE3-BGHpA (Alias: CN3755) (#214846). In addition to the viral particles, you will also receive purified AiP13755: pAAV-AiE0743m_3xC2-minBG-ChR2(H134R)-EYFP-WPRE3-BGHpA (Alias: CN3755) plasmid DNA. minBG-driven expression of ChR2(H134R)-EYFP in striatal cholinergic neurons. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

   Depositor

   The Allen Institute for Brain Science, Jonathan Ting

   Article

   Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

   Promoter

   Tags

   EYFP

   Available since

   Nov. 13, 2024

   Availability

   Academic Institutions and Nonprofits only

5. AiP13778 - pAAV-AiE0450h-minBG-iCre(R297T)-BGHpA (Alias: CN3778) (AAV PHP.eB)

   Viral Prep

   #199775-PHPeB

   Purpose

   Ready-to-use AAV PHP.eB particles produced from AiP13778 - pAAV-AiE0450h-minBG-iCre(R297T)-BGHpA (Alias: CN3778) (#199775). In addition to the viral particles, you will also receive purified AiP13778 - pAAV-AiE0450h-minBG-iCre(R297T)-BGHpA (Alias: CN3778) plasmid DNA. Cre recombinase expression in striatal medium spiny neurons. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

   Depositor

   The Allen Institute for Brain Science, Jonathan Ting

   Article

   Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

   Promoter

   Tags

   None

   Available since

   July 15, 2024

   Availability

   Academic Institutions and Nonprofits only

6. pAAV_BiPVe4_dTomato_nlsdTomato (AAV PHP.eB)

   Viral Prep

   #213936-PHPeB

   Purpose

   Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe4_dTomato_nlsdTomato (#213936). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the chandelier cell-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Gordon Fishell

   Article

   Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

   Promoter

   Tags

   dTomato

   Available since

   Dec. 2, 2024

   Availability

   Academic Institutions and Nonprofits only

7. pAAV-CKIIa-stGtACR2-FusionRed (AAV1)

   Viral Prep

   #105669-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pAAV-CKIIa-stGtACR2-FusionRed (#105669). In addition to the viral particles, you will also receive purified pAAV-CKIIa-stGtACR2-FusionRed plasmid DNA. CaMKIIa-driven, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Ofer Yizhar

   Article

   Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

   Promoter

   CaMKII

   Tags

   FusionRed

   Available since

   July 17, 2018

   Availability

   Academic Institutions and Nonprofits only

8. pAAV_hSyn1-SIO-stGtACR1-FusionRed (AAV5)

   Viral Prep

   #105678-AAV5

   Purpose

   Ready-to-use AAV5 particles produced from pAAV_hSyn1-SIO-stGtACR1-FusionRed (#105678). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR1-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Ofer Yizhar

   Article

   Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

   Promoter

   Syn

   Tags

   FusionRed (Cre-dependent)

   Available since

   Sept. 24, 2020

   Availability

   Academic Institutions and Nonprofits only

9. pAAV_hSyn1-SIO-stGtACR2-FusionRed (AAV5)

   Viral Prep

   #105677-AAV5

   Purpose

   Ready-to-use AAV5 particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Ofer Yizhar

   Article

   Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

   Promoter

   Syn

   Tags

   FusionRed (Cre-dependent)

   Available since

   Oct. 21, 2024

   Availability

   Academic Institutions and Nonprofits only

10. pAAV_hSyn1-SIO-stGtACR2-FusionRed (AAV1)

    Viral Prep

    #105677-AAV1

    Purpose

    Ready-to-use AAV1 particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Ofer Yizhar

    Article

    Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

    Promoter

    Syn

    Tags

    FusionRed (Cre-dependent)

    Available since

    Aug. 17, 2018

    Availability

    Academic Institutions and Nonprofits only

11. pAAV-CKIIa-stGtACR2-FusionRed (AAV Retrograde)

    Viral Prep

    #105669-AAVrg

    Purpose

    Ready-to-use AAV Retrograde particles produced from pAAV-CKIIa-stGtACR2-FusionRed (#105669). In addition to the viral particles, you will also receive purified pAAV-CKIIa-stGtACR2-FusionRed plasmid DNA. CaMKIIa-driven, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Ofer Yizhar

    Article

    Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

    Promoter

    CaMKII

    Tags

    FusionRed

    Available since

    July 8, 2020

    Availability

    Academic Institutions and Nonprofits only

12. pAAV_hSyn1-SIO-stGtACR2-FusionRed (AAV Retrograde)

    Viral Prep

    #105677-AAVrg

    Purpose

    Ready-to-use AAV Retrograde particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Ofer Yizhar

    Article

    Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

    Promoter

    Syn

    Tags

    FusionRed (Cre-dependent)

    Available since

    July 8, 2020

    Availability

    Academic Institutions and Nonprofits only

13. pAAV-CaMKIIa-ChRmine-oScarlet-KV 2.1-WPRE (AAV8)

    Viral Prep

    #183519-AAV8

    Purpose

    Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-ChRmine-oScarlet-KV 2.1-WPRE (#183519). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-ChRmine-oScarlet-KV 2.1-WPRE plasmid DNA. CaMKIIa-driven expression of ChRmine-oScarlet-KV 2.1. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Karl Deisseroth

    Article

    Kishi et al Cell. 2022 Feb 17;185(4):672-689.e23. do

    Promoter

    CaMKII

    Tags

    None

    Available since

    Dec. 18, 2024

    Availability

    Academic Institutions and Nonprofits only

14. pAAV_BiSSTe4_dTomato_nlsdTomato (AAV PHP.eB)

    Viral Prep

    #213944-PHPeB

    Purpose

    Ready-to-use AAV PHP.eB particles produced from pAAV_BiSSTe4_dTomato_nlsdTomato (#213944). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the SST interneuron-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Gordon Fishell

    Article

    Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

    Promoter

    Tags

    dTomato

    Available since

    Dec. 2, 2024

    Availability

    Academic Institutions and Nonprofits only

15. pAAV_BiSSTe10_dTomato_nlsdTomato (AAV PHP.eB)

    Viral Prep

    #213814-PHPeB

    Purpose

    Ready-to-use AAV PHP.eB particles produced from pAAV_BiSSTe10_dTomato_nlsdTomato (#213814). In addition to the viral particles, you will also receive purified pAAV_BiSSTe10_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the SST interneuron-targeting enhancer E10. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Gordon Fishell

    Article

    Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

    Promoter

    Tags

    dTomato

    Available since

    Dec. 2, 2024

    Availability

    Academic Institutions and Nonprofits only

16. pAAV_BiVIPe4_dTomato_nlsdTomato (AAV PHP.eB)

    Viral Prep

    #213855-PHPeB

    Purpose

    Ready-to-use AAV PHP.eB particles produced from pAAV_BiVIPe4_dTomato_nlsdTomato (#213855). In addition to the viral particles, you will also receive purified pAAV_BiVIPe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the VIP interneuron-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Gordon Fishell

    Article

    Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

    Promoter

    Tags

    dTomato

    Available since

    Dec. 2, 2024

    Availability

    Academic Institutions and Nonprofits only

17. pAAV_BiPVe3_dTomato_nlsdTomato (AAV PHP.eB)

    Viral Prep

    #213940-PHPeB

    Purpose

    Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe3_dTomato_nlsdTomato (#213940). In addition to the viral particles, you will also receive purified pAAV_BiPVe3_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the PV+ basket cell-targeting enhancer E3. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Gordon Fishell

    Article

    Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

    Promoter

    Tags

    dTomato

    Available since

    Dec. 2, 2024

    Availability

    Academic Institutions and Nonprofits only

18. pACAGW-ChR2-Venus-AAV (AAV1)

    Viral Prep

    #20071-AAV1

    Purpose

    Ready-to-use AAV1 particles produced from pACAGW-ChR2-Venus-AAV (#20071). In addition to the viral particles, you will also receive purified pACAGW-ChR2-Venus-AAV plasmid DNA. CAG-driven, channelrhodopsin fused to Venus for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Karel Svoboda

    Article

    Leopoldo et al Nature. 2009 Jan 18.

    Promoter

    CAGG

    Tags

    Venus

    Available since

    Feb. 21, 2018

    Availability

    Academic Institutions and Nonprofits only

19. pACAGW-ChR2-Venus-AAV (AAV9)

    Viral Prep

    #20071-AAV9

    Purpose

    Ready-to-use AAV9 particles produced from pACAGW-ChR2-Venus-AAV (#20071). In addition to the viral particles, you will also receive purified pACAGW-ChR2-Venus-AAV plasmid DNA. CAG-driven, channelrhodopsin fused to Venus for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Karel Svoboda

    Article

    Leopoldo et al Nature. 2009 Jan 18.

    Promoter

    CAGG

    Tags

    Venus

    Available since

    March 15, 2018

    Availability

    Academic Institutions and Nonprofits only

20. AAV-GfaABC1D-Cre-4x6T (AAV5)

    Viral Prep

    #196410-AAV5

    Purpose

    Ready-to-use AAV5 particles produced from AAV-GfaABC1D-Cre-4x6T (#196410). In addition to the viral particles, you will also receive purified AAV-GfaABC1D-Cre-4x6T plasmid DNA. GfaABC1D driven expression of Cre recombinase in astrocytes. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Stanley Thomas Carmichael

    Article

    Gleichman et al Nat Commun. 2023 Nov 16;14(1):7426. doi:

    Promoter

    CAG and GfaABC1D

    Tags

    None

    Available since

    Sept. 27, 2024

    Availability

    Academic Institutions and Nonprofits only